Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival

Cancer Science

Volumn 102, Issue 5, 2011, Pages 1101-1106

  Satoh, Naoyuki ^a   Maniwa, Yoshimasa ^b   Bermudez, Vladimir P ^b   Nishimura, Kunihiro ^b   Nishio, Wataru ^b   Yoshimura, Masahiro ^b   Okita, Yutaka ^b   Ohbayashi, Chiho ^c   Hurwitz, Jerard ^b   Hayashi, Yoshitake ^a  

^a Department of Pathology   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H2AX; KI 67 ANTIGEN; PHOSPHATASE; TUMOR MARKER; UNCLASSIFIED DRUG; WIP1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY VEIN; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPROTEIN PHOSPHATASES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79954664195     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01898.x     Document Type: Article

References (33)

1. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-96.
2. Shiloh Y. ATM and related protein kinase: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-68.
3. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-13.
4. Bartkova J, Horejsí Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-70.
5. Bonner WM, Redon CE, Dickey JS et al. γH2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
6. Mah LJ, El-Osta A, Karagiannis TC. γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24: 679-86.
7. Yu T, MacPhail SH, Banáth JP et al. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 2006; 5: 935-46.
8. Moorhead GB, Trinkle-Mulcahy L, Ulke-Lemée A. Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol 2007; 8: 234-44.
9. Jackson MD, Denu JM. Molecular reactions of protein phosphatases - insights from structure and chemistry. Chem Rev 2001; 101: 2313-40.
10. Fiscella M, Zhang H, Fan S et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 1997; 94: 6048-53.
11. Lu X, Nguyen TA, Moon SH et al. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008; 27: 123-35.
12. Cha H, Lowe JM, Li H et al. Wip1 directly dephosphorylates γ-H2AX and attenuates the DNA damage response. Cancer Res 2010; 70: 4112-22.
13. Moon SH, Lin L, Zhang X et al. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant γ-H2AX and suppresses DNA double strand break repair. J Biol Chem 2010; 285: 12935-47.
14. Bulavin DV, Demidov ON, Saito S et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210-5.
15. Bulavin DV, Phillips C, Nannenga B et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004; 36: 343-50.
16. Rauta J, Alarmo EL, Kauraniemi P et al. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 2006; 95: 257-63.
17. Hirasawa A, Saito-Ohara F, Inoue J et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9: 1995-2004.
18. Saito-Ohara F, Imoto I, Inoue J et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876-83.
19. Loukopoulos P, Shibata T, Katoh H et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007; 98: 392-400.
20. Coombs NJ, Gough AC, Primrose JN. Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 1999; 27: e12.
21. Nagai Y, Miyazawa H, Huqun et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-82.
22. Minami H, Yoshimura M, Miyamoto Y et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000; 118: 1603-9.
23. Nannenga B, Lu X, Dumble M et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006; 45: 594-604.
24. Demidov ON, Kek C, Shreeram S et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007; 26: 2502-6.
25. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-5.
26. Beckman RA, Loeb LA. Efficiency of carcinogenesis with and without a mutator mutation. Proc Natl Acad Sci U S A 2006; 103: 14140-5.
27. Bennett WP, Hussain SP, Vahakangas KH et al. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 8-18.
28. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 2003; 24: 141-56.
29. Passlick B, Izbicki JR, Riethmüller G et al. p53 in non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 801-3.
30. Lee JS, Yoon A, Kalapurakal SK et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-903.
31. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
32. Kosaka T, Yatabe Y, Onozato R et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009; 4: 22-9.
33. Ventura JJ, Tenbaum S, Perdiguero E et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39: 750-8.